We are live on ! Find out more

NVO

Novo Nordisk

NVO

Market cap $191B

43.24 USD

+0.05

0.12%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

43.30

+0.06

0.14%

1 day

0.12%

5 days

-0.96%

1 month

-5.4%

3 months

0.12%

6 months

15.46%

Year to date

-17.47%

1 year

-30.09%

5 years

-13.22%

10 years

89.07%

About: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 69,500

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 45.3%

Neutral 22.9%

Negative 31.8%

Zacks Investment Research

Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union

NVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.

Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European Union

40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"

Raul Shah (@Raul_DSF) is very bullish on the future of GLP-1s due to accelerating demand trends generating a "mania" effect in the market. He points to the superiority Eli Lilly (LLY) has demonstrated through earnings and weighs if Novo (NVO) has a chance to catch up.

40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"

EMA Committee Endorses Novo Nordisk's Hemophilia A Therapy

Novo Nordisk A/S (NYSE:NVO) stock is trading higher on Thursday after the Danish drug maker achieved major advances across its therapeutic pipeline after securing a key European regulatory recommendation for its hemophilia A treatment and launching a major cardiometabolic research partnership.

EMA Committee Endorses Novo Nordisk's Hemophilia A Therapy

Zacks Investment Research

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

Zacks Investment Research

Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery

NVO is expanding its AI strategy with Anthropic to tackle drug discovery challenges, boost R&D productivity and develop new medicines faster.

Novo Expands AI Push With Anthropic Deal to Accelerate Drug Discovery

Zacks Investment Research

Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?

NVO's 5% drop in a week reflects intensifying GLP-1 competition and semaglutide risks, but its broad pipeline offers potential long-term growth.

Novo Falls 5% in a Week: How Should Investors Approach the Stock Now?

Novo, Orbis sign up to $1.4 billion deal to develop oral drugs

Orbis Medicines said on Thursday it had signed a drug discovery and licensing deal with Novo Nordisk worth up to $1.4 billion to develop oral therapies for cardiometabolic diseases that are ‌traditionally treated with injectable drugs.

Novo, Orbis sign up to $1.4 billion deal to develop oral drugs

Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion

COPENHAGEN, Denmark--(BUSINESS WIRE)--Orbis Medicines, a leader in oral macrocycle drug discovery, today announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. The agreement enables the acceleration of the development of a new class of orally available medicines for high-value therapeutic targets. Under the terms of the agreement, Orbis Medicines is eligible to receive up to U.

Orbis Medicines Enters Multi-Target Drug Discovery Partnership with Novo Nordisk Worth up to USD 1.4 Billion

Zacks Investment Research

Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note

Novo Nordisk (NVO) closed the most recent trading day at $41.67, moving 2.02% from the previous trading session.

Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note

Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It.

Novo Nordisk and Anthropic strike a partnership to leverage Claude and other AI models in the drug development process.

Will AI Save the Pharma Industry Billions? Novo's Anthropic Deal Is Betting on It.

See News Rankings

Price charts implemented using Lightweight Charts™